Giletti A, Vital M, Lorenzo M, Cardozo P, Borelli G, Gabus R, et al. Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases. Eur J Pharm Sci. 2017 Nov;109:480–5.

Chan ESL, Cronstein BN. Mechanisms of action of methotrexate. Bull Hosp Joint Dis. 2013;

Bedoui Y, Guillot X, Sélambarom J, Guiraud P, Giry C, Jaffar-Bandjee MC, et al. Methotrexate an old drug with new tricks. International Journal of Molecular Sciences. 2019.

Helal MG, Said E. Tranilast attenuates methotrexate-induced renal and hepatic toxicities: Role of apoptosis-induced tissue proliferation. J Biochem Mol Toxicol. 2020 May 1;34(5):e22466.

Mehrzadi S, Fatemi I, Esmaeilizadeh M, Ghaznavi H, Kalantar H, Goudarzi M. Hepatoprotective effect of berberine against methotrexate induced liver toxicity in rats. Biomedicine and Pharmacotherapy. 2018 Jan 1;97:233–9.

May J, Carson KR, Butler S, Liu W, Bartlett NL, Wagner-Johnston ND. High incidence of methotrexate associated renal toxicity in patients with lymphoma: A retrospective analysis. Leuk Lymphoma. 2014;

Cheng KKF. Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer: Case report. Eur J Cancer Care (Engl). 2008;

Salkade PR, Lim TA. Methotrexate-induced acute toxic leukoencephalopathy. J Cancer Res Ther. 2012 Apr;8(2):292–6.

Bacci G, Ferrari S, Longhi A, Forni C, Loro L, Beghelli C, et al. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy. Oncol Rep. 2003;

Sajith M, Pawar A, Momin AA, Bafna V, Bartakke S. Evaluation of Relationship of the Methylene Tetrahydrofolate Reductase Enzyme Polymorphisms with Serum Methotrexate Concentration and Toxicity in Acute Lymphoblastic Leukemia Patients Treated with High Dose Methotrexate Infusion. Journal of Krishna Institute of Medical Sciences University. 2020;9(3):27–39.

Ezhilarasan D. Hepatotoxic potentials of methotrexate: Understanding the possible toxicological molecular mechanisms. Toxicology [Internet]. 2021 Jun 30 [cited 2022 Nov 19];458. Available from: https://pubmed.ncbi.nlm.nih.gov/34175381/

Yoon WS, Park JS, Kim Y il, Chung DS, Jeun SS, Hong YK, et al. High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience. Asia Pac J Clin Oncol [Internet]. 2021 Feb 1 [cited 2022 Nov 19];17(1):123–30. Available from: https://pubmed.ncbi.nlm.nih.gov/32978898/

Campbell JM, Bateman E, Stephenson MD, Bowen JM, Keefe DM, Peters MDJ. Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Cancer Chemother Pharmacol. 2016 Jul;78(1):27–39.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. J Am Med Assoc. 2000;

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. In: Journal of clinical epidemiology. 2009.

Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. 2009;

Cheung MWL, Ho RCM, Lim Y, Mak A. Conducting a meta-analysis: Basics and good practices. Int J Rheum Dis. 2012;

Lim RBC, Zhang MWB, Ho RCM. Prevalence of all-cause mortality and suicide among bariatric surgery cohorts: A meta-analysis. International Journal of Environmental Research and Public Health. 2018.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal. 2003.

Christensen AM, Pauley JL, Molinelli AR, Panetta JC, Ward DA, Stewart CF, et al. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer. 2012 Sep;118(17):4321–30.

Haase R, Elsner K, Merkel N, Stiefel M, Mauz-Körholz C, Kramm CM, et al. High dose methotrexate treatment in childhood ALL: pilot study on the impact of the MTHFR 677C>T and 1298A>C polymorphisms on MTX-related toxicity. Klin Padiatr. 2012 Apr;224(3):156–9.

Kantar M, Kosova B, Cetingul N, Gumus S, Toroslu E, Zafer N, et al. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma. 2009 Jun;50(6):912–7.

Mandal P, Samaddar S, Chandra J, Parakh N, Goel M. Adverse effects with intravenous methotrexate in children with acute lymphoblastic leukemia/lymphoma: a retrospective study. Indian Journal of Hematology and Blood Transfusion. 2020;36(3):498–504.

Rask C, Albertioni F, Bentzen SM, Schroeder H, Peterson C. Clinical and pharmacokinetic risk factors for high-dose methotrexate- induced toxicity in children with acute lymphoblastic leukemia - A logistic regression analysis. Acta Oncol (Madr). 1998;37(3):277–84.

van Kooten Niekerk PB, Schmiegelow K, Schroeder H. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate. Eur J Haematol. 2008 Nov;81(5):391–8.

D'Angelo V, Ramaglia M, Iannotta A, Crisci S, Indolfi P, Francese M, et al. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. Cancer Chemother Pharmacol. 2011 Nov;68(5):1339–46.

D'Angelo V, Ramaglia M, Iannotta A, Francese M, Pota E, Affinita MC, et al. Influence of methylenetetrahydrofolate reductase gene polymorphisms on the outcome of pediatric patients with non-Hodgkin lymphoma treated with high-dose methotrexate. Leuk Lymphoma. 2013 Dec;54(12):2639–44.

Kishi S, Griener J, Cheng C, Das S, Cook EH, Pei D, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol. 2003 Aug;21(16):3084–91.

Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet. 2007;52(2):166–71.

Liu SG, Li ZG, Cui L, Gao C, Li WJ, Zhao XX. Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population. Leuk Lymphoma. 2011 Jun;52(6):1030–40.

Esmaili MA, Kazemi A, Faranoush M, Mellstedt H, Zaker F, Safa M, et al. Polymorphismswithinmethotrexatepathwaygenes:Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia. Iran J Basic Med Sci. 2020 Jun 1;23(6):800–9.

Faganel Kotnik B, Grabnar I, Bohanec Grabar P, Dolžan V, Jazbec J. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol. 2011 Oct;67(10):993–1006.

Kotnik BF, Jazbec J, Grabar PB, Rodriguez-Antona C, Dolzan V. Association between SLC19A1 Gene Polymorphism and High Dose Methotrexate Toxicity in Childhood Acute Lymphoblastic Leukaemia and Non Hodgkin Malignant Lymphoma: Introducing a Haplotype based Approach. Radiol Oncol. 2017 Dec;51(4):455–62.

Kotur N, Lazic J, Ristivojevic B, Stankovic B, Gasic V, Dokmanovic L, et al. Pharmacogenomic markers of methotrexate response in the consolidation phase of pediatric acute lymphoblastic leukemia treatment. Genes (Basel). 2020;11(4):1–17.

Xue Y, Rong L, Tong N, Wang M, Zhang Z, Fang Y. CCND1 G870A polymorphism is associated with toxicity of methotrexate in childhood acute lymphoblastic leukemia. Int J Clin Exp Pathol. 2015;8(9):11594–600.

Yousef AM, Farhad R, Alshamaseen D, Alsheikh A, Zawiah M, Kadi T. Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2019 Apr;83(4):755–62.

Sajith M, Pawar A, Bafna V, Bartakke S, Subramanian K, Vaidya N. Serum Methotrexate Level and Side Effects of High Dose Methotrexate Infusion in Pediatric Patients with Acute Lymphoblastic Leukaemia (ALL). INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION. 2020 Jan;36(1):51–8.

Erculj N, Kotnik BF, Debeljak M, Jazbec J, Dolzan V. The influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in children with non-Hodgkin malignant lymphoma. Radiol Oncol. 2014 Sep;48(3):289–92.

Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Piñan MA, Garcia-Miguel P, Navajas A, et al. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011 Oct;57(4):612–9.

Lopez-Lopez E, Ballesteros J, Piñan MA, Sanchez de Toledo J, Garcia de Andoin N, Garcia-Miguel P, et al. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics. 2013 Feb;23(2):53–61.

Panetta JC, Roberts JK, Huang J, Lin T, Daryani VM, Harstead KE, et al. Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours. Br J Clin Pharmacol. 2020 Feb;86(2):362–71.

Tsurusawa M, Gosho M, Mori T, Mitsui T, Sunami S, Kobayashi R, et al. Statistical Analysis of Relation Between Plasma Methotrexate Concentration and Toxicity in High-Dose Methotrexate Therapy of Childhood NonHodgkin Lymphoma. Pediatr Blood Cancer. 2015 Feb;62(2):279–84.

Erčulj N, Kotnik BF, Debeljak M, Jazbec J, Dolžan V. Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2012 Jun;53(6):1096–104.

Li J, Wang XR, Zhai XW, Wang HS, Qian XW, Miao H, et al. Association of SLCO1B1 gene polymorphisms with toxicity response of high dose methotrexate chemotherapy in childhood acute lymphoblastic leukemia. Int J Clin Exp Med. 2015;8(4):6109–13.

Razali RH, Noorizhab MNF, Jamari H, James RJ, Teh KH, Ibrahim HM, et al. Association of ABCC2 with levels and toxicity of methotrexate in Malaysian Childhood Acute Lymphoblastic Leukemia (ALL). Pediatr Hematol Oncol. 2020 Apr;37(3):185–97.

Yazıcıoğlu B, Kaya Z, Güntekin Ergun S, Perçin F, Koçak Ü, Yenicesu İ, et al. Influence of Folate-Related Gene Polymorphisms on High-Dose Methotrexate-Related Toxicity and Prognosis in Turkish Children with Acute Lymphoblastic Leukemia. Turk J Haematol. 2017 Jun;34(2):143–50.

den Hoed MAH, Lopez-Lopez E, te Winkel ML, Tissing W, de Rooij JDE, Gutierrez-Camino A, et al. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia. Pharmacogenomics J. 2015 Jun;15(3):248–54.

Gutierrez-Camino A, Oosterom N, den Hoed MAH, Lopez-Lopez E, Martin-Guerrero I, Pluijm SMF, et al. The miR-1206 microRNA variant is associated with methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics. 2017 Aug;27(8):303–6.

Kawakatsu S, Nikanjam M, Lin M, Le S, Saunders I, Kuo DJ, et al. Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients. Cancer Chemother Pharmacol. 2019 Dec;84(6):1339–48.

Kloos RQH, Pieters R, van den Bos C, van Eijkelenburg NKA, de Jonge R, van der Sluis IM. The effect of asparaginase therapy on methotrexate toxicity and efficacy in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2019 Oct;60(12):3002–10.

Oosterom N, de Jonge R, Smith DEC, Pieters R, Tissing WJE, Fiocco M, et al. Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia. PLoS One. 2019 Sep;14(9).

Park JA, Shin HY. Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma. Blood Res. 2016 Mar 1;51(1):50–7.

Hegyi M, Arany A, Semsei AF, Csordas K, Eipel O, Gezsi A, et al. Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma. Oncotarget. 2017 Feb;8(6):9388–98.

Lambrecht L, Sleurs C, Labarque V, Dhooge C, Laenen A, Sinnaeve F, et al. The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients. Pharmacogenomics. 2017 Jun 1;18(8).

Young EP, Cheng WS, Bernhardt MB, Wang LL, Rainusso N, Foster JH. Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma. Pediatr Blood Cancer. 2020 Apr 22;67(4):e28123.

Patino-Garcia A, Zalacain M, Marrodan L, San-Julian M, Sierrasesumaga L. Methotrexate in Pediatric Osteosarcoma: Response and Toxicity in Relation to Genetic Polymorphisms and Dihydrofolate Reductase and Reduced Folate Carrier 1 Expression. JOURNAL OF PEDIATRICS. 2009 May;154(5):688–93.

Camitta B, Leventhal B, Lauer S, Shuster JJ, Adair S, Casper J, et al. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: A pediatric Oncology Group study. Journal of Clinical Oncology. 1989;7(10):1539–44.

Camitta B, Mahoney D, Leventhal B, Lauer SJ, Shuster JJ, Adair S, et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher- risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group Study. Journal of Clinical Oncology. 1994;12(7):1383–9.

Farrow AC, Buchanan GR, Zwiener RJ, Bowman WP, Winick NJ. Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. Journal of Clinical Oncology. 1997;15(4):1560–6.

Lu S, Zhu X, Li W, Chen H, Zhou D, Zhen Z, et al. Influence of Methylenetetrahydrofolate Reductase C677T and A1298C Polymorphism on High-Dose Methotrexate-Related Toxicities in Pediatric Non-Hodgkin Lymphoma Patients. Front Oncol. 2021;11(February):1–9.

Gong F, Meng Q, Liu C, Zhao Y. Efficacy and association analysis of high-dose methotrexate in the treatment of children with acute lymphoblastic leukemia. Oncol Lett. 2019;17(5):4423–8.

Skapek SX, Ferguson WS, Granowetter L, Devidas M, Perez-Atayde AR, Dehner LP, et al. Vinblastine and methotrexate for desmoid fibromatosis in children: Results of a Pediatric Oncology Group phase II trial. Journal of Clinical Oncology. 2007;25(5):501–6.

Shimasaki N, Mori T, Samejima H, Sato R, Shimada H, Yahagi N, et al. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2006 Feb;28(2):64–8.

Khera S, Kapoor R, Pramanik SK. Solitary serum methotrexate level 36 hours post high-dose methotrexate: A safe, efficacious, and cost-effective strategy to monitor methotrexate toxicities in childhood leukemia in resource-limited centers. Pediatr Blood Cancer. 2020;67(7).

Hegyi M, Arany A, Semsei AF, Csordas K, Eipel O, Gezsi A, et al. Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma. Oncotarget. 2017 Oct;8(6):9388–98.

Howard SC, McCormick J, Pui C, Buddington RK, Harvey RD. Preventing and Managing Toxicities of High‐Dose Methotrexate. Oncologist. 2016;21(12):1471–82.

Ahmed AAM, Selim MAA, El-Sayed NM. α-Lipoic acid ameliorates oral mucositis and oxidative stress induced by methotrexate in rats. Histological and immunohistochemical study. Life Sci. 2017 Feb 15;171:51–9.

Bath RK, Brar NK, Forouhar FA, Wu GY. A review of methotrexate-associated hepatotoxicity. J Dig Dis. 2014 Oct 1;15(10):517–24.

Howard SC, McCormick J, Pui C, Buddington RK, Harvey RD. Preventing and Managing Toxicities of High‐Dose Methotrexate. Oncologist. 2016;

Holmboe L, Andersen AM, Mørkrid L, Slørdal L, Hall KS. High dose methotrexate chemotherapy: Pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol. 2012 Jan;73(1):106–14.

Al Maruf A, O'Brien PJ, Naserzadeh P, Fathian R, Salimi A, Pourahmad J. Methotrexate induced mitochondrial injury and cytochrome c release in rat liver hepatocytes. Drug Chem Toxicol. 2018;41(1):51–61.

Esmaili MA, Kazemi A, Faranoush M, Mellstedt H, Zaker F, Safa M, et al. Polymorphismswithinmethotrexatepathwaygenes:Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia. Iran J Basic Med Sci. 2020 Jun 1;23(6):800–9.

Georgiou KR, Nadhanan RR, Fan CM, Xian CJ. Methotrexate-induced bone marrow adiposity Is mitigated by folinic acid supplementation through the regulation of Wnt/β-catenin signalling. J Cell Physiol. 2015 Mar 1;230(3):648–56.

Pokrovsky VS, Vinnikov D. Defining the toxicity of current regimens for extranodal NK/T cell lymphoma: a systematic review and metaproportion. Expert Rev Anticancer Ther. 2019;

Isoardi KZ, Harris K, Carmichael KE, Dimeski G, Chan BSH, Page CB. Acute bone marrow suppression and gastrointestinal toxicity following acute oral methotrexate overdose. Clin Toxicol. 2018;

Relling M V, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999 Dec;91(23):2001–8.

Luu B, Rodway GW. Does low-dose methotrexate deserve more respect from clinicians? Journal of the American Academy of Physician Assistants. 2017.

Grönroos MH, Jahnukainen T, Möttönen M, Perkkiö M, Irjala K, Salmi TT. Long-term follow-up of renal function after high-dose methotrexate treatment in children. Pediatr Blood Cancer. 2008 Oct 1;51(4):535–9.

Yang Y, Wang X, Tian J, Wang Z. Renal function and plasma methotrexate concentrations predict toxicities in adults receiving high-dose methotrexate. Medical Science Monitor. 2018 Oct 29;24(2):7719–26.

Afshar M, Birnbaum D, Golden C. Pediatric Neurology Review of Dextromethorphan Administration in 18 Patients With Subacute Methotrexate Central Nervous System Toxicity. Pediatr Neurol. 2014;50(6):625–9.

Cronstein B, Naime D, Clinical EOTJ of, 1993 U. antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. Am Soc Clin Investig. 1993;92:2675-2682.

Driehuis E, Oosterom N, Heil SG, Muller IB, Lin M, Kolders S, et al. Patient-derived oral mucosa organoids as an in vitro model for methotrexate induced toxicity in pediatric acute lymphoblastic leukemia (vol 15, e0231588, 2020). PLoS One. 2020 Aug;15(8).

Papaconstantinou HT, Xie C, Zhang W, Ansari NH, Hellmich MR, Townsend CM, et al. The role of caspases in methotrexate-induced gastrointestinal toxicity. Surgery. 2001;

Natarajan K, Abraham P, Kota R. Activation of the mitochondrial apoptotic pathway contributes to methotrexate-induced small intestinal injury in rats. Cell Biochem Funct. 2017;

Kataria P, Kendre P, Patel A, Tahiliani N, Ikhar S. Methotrexate-Induced Toxic Epidermal Necrolysis: A Rare Case Report and Review of Literature. INDIAN JOURNAL OF CRITICAL CARE MEDICINE. 2018 Oct;22(10):740–2.

Song X, Guo Y, Zhao H, Hu W. Skin and mucosal ulcerations and acute kidney failure due to methotrexate toxicity in a patient with non-Hodgkin's lymphoma. Indian Journal of Cancer. 2018.

Primka EJ, Camisa C. Methotrexate-induced toxic epidermal necrolysis in a patient with psoriasis. J Am Acad Dermatol. 1997;

Liu Y, Yin Y, Sheng Q, Lu X, Wang F, Lin Z, et al. Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. PLoS One. 2014;9(1):e82681.

Nathan PC, Whitcomb T, Wolters PL, Steinberg SM, Balis FM, Brouwers P, et al. Very high-dose methotrexate (33.6 g/m2) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: Results of National Cancer Institute/Children's Cancer Group Trials CCG-191P, CCG-134P and CCG-144P. Leuk Lymphoma. 2006;47(12):2488–504.

Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman WP, et al. Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic Leukemia. New England Journal of Medicine. 1986 Feb 20;314(8):471–7.

Young EP, Cheng WS, Bernhardt MB, Wang LL, Rainusso N, Foster JH. Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma. Pediatr Blood Cancer. 2020 Apr 1;67(4).

Chae H, Kim M, Choi SH, Kim SK, Lee JW, Chung NG, et al. Influence of plasma methotrexate level and MTHFR genotype in Korean paediatric patients with acute lymphoblastic leukaemia. J Chemother. 2020 Sep;32(5):251–9.

Buaboonnam J, Cao X, Pauley JL, Pui CH, Ribeiro RC, Rubnitz JE, et al. Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2013 Jul;60(7):1161–4.

Hays H, Beuhler MC, Spiller HA, Weber J, Mowry JB, Ryan ML, et al. Evaluation of toxicity after acute accidental methotrexate ingestions in children under 6 years old: a 16-year multi-center review. Clin Toxicol. 2018;56(2):120–5.

Lauer SJ, Camitta BM, Leventhal BG, Mahoney D, Shuster JJ, Kiefer G, et al. Intensive alternating drug pairs after remission induction for treatment of infants with acute lymphoblastic leukemia: A pediatric oncology group pilot study. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY. 1998;20(3):229–33.

Patte C, Philip T, Rodary C, Zucker JM, Behrendt H, Gentet JC, et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: Results from the french pediatric oncology society of a randomized trial of 216 children. Journal of Clinical Oncology. 1991;9(1):123–32.

Pompe RS, Von Bueren AO, Mynarek M, Von Hoff K, Friedrich C, Kwiecien R, et al. Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy. Eur J Cancer. 2015;51(17):2634–42.

Oosterom N, Griffioen PH, den Hoed MAH, Pieters R, de Jonge R, Tissing WJE, et al. Global methylation in relation to methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia. PLoS One. 2018 Jul;13(7).

Skapek SX, Ferguson WS, Granowetter L, Devidas M, Perez-Atayde AR, Dehner LP, et al. Vinblastine and methotrexate for desmoid fibromatosis in children: Results of a Pediatric Oncology Group phase II trial. JOURNAL OF CLINICAL ONCOLOGY. 2007 Feb;25(5):501–6.

Tower RL, Jones TL, Camitta BM, Asselin BL, Bell BA, Chauvenet A, et al. Dose Intensification of Methotrexate and Cytarabine During Intensified Continuation Chemotherapy for High-risk B-Precursor Acute Lymphoblastic Leukemia: POG 9406: A Report From the Children's Oncology Group. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY. 2014 Jul;36(5):353–61.

Vaishnavi K, Bansal D, Trehan A, Jain R, Attri SV. Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin. Pediatr Blood Cancer. 2018;65(12).

Valer JB, Curra M, Gabriel A de F, Schmidt TR, Ferreira MBC, Roesler R, et al. Oral mucositis in childhood cancer patients receiving high-dose methotrexate: Prevalence, relationship with other toxicities and methotrexate elimination. Int J Paediatr Dent. 2021;31(2):238–46.

Van Hasselt JGC, Van Eijkelenburg NKA, Huitema ADR, Schellens JHM, Schouten-Van Meeteren AYN. Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate. Antimicrob Agents Chemother. 2013 Jun;57(6):2878–81.

Winick NJ, Bowman WP, Kamen BA, Roach ES, Rollins N, Jacaruso D, et al. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst. 1992;84(4):252–6.

Foster JH, Thompson PA, Bernhardt MB, Margolin JF, Hilsenbeck SG, Jo E, et al. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities. Cancer Chemother Pharmacol. 2019 Feb;83(2):349–60.

de Carvalho DC, Wanderley AV, dos Santos AMR, Fernandes MR, Cohen Lima de Castro A de N, Leitão LPC, et al. Pharmacogenomics and variations in the risk of toxicity during the consolidation/maintenance phases of the treatment of pediatric B-cell leukemia patients from an admixed population in the Brazilian Amazon. Leuk Res. 2018;74(May):10–3.

Wolff JE, Kortmann RD, Wolff B, Pietsch T, Peters O, Schmid HJ, et al. High dose methotrexate for pediatric high grade glioma - Results of the HIT-GBM-D Pilot study. J Neurooncol. 2011;102(3):433–42.

Zhu XJ, He XL, Wu YP, Zou RY, Li WL, Zou H, et al. [Influence of thymidylate synthase gene polymorphisms on high-dose methotrexate-related toxicities in childhood acute lymphoblastic leukemia]. Zhongguo Dang Dai Er Ke Za Zhi. 2015 Jan;17(1):11–4.

Mateos MK, Marshall GM, Barbaro PM, Quinn MC, George C, Mayoh C, et al. Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia. Haematologica. 2021;

Freeman AI, Weinberg V, Brecher ML, Jones B, Glicksman AS, Sinks LF, et al. Comparison of Intermediate-Dose Methotrexate with Cranial Irradiation for the Post-Induction Treatment of Acute Lymphocytic Leukemia in Children. New England Journal of Medicine. 1983 Mar 3;308(9):477–84.

Larsen EC, Devidas M, Chen S, Salzer WL, Raetz EA, Loh ML, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: A report from children's oncology group study AALL0232. Journal of Clinical Oncology. 2016;34(20):2380–8.

Ochs J, Rodman J, Abromowitch M, Kavanagh R, Harris M, Yalowich J, et al. A phase II study of combined methotrexate and teniposide infusions prior to reinduction therapy in relapsed childhood acute lymphoblastic leukemia: A pediatric oncology group study. Journal of Clinical Oncology. 1991;9(1):139–44.